Omega Financial Statements From 2010 to 2025

OMGA Stock  USD 0.52  0.04  7.29%   
Omega Therapeutics financial statements provide useful quarterly and yearly information to potential Omega Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Omega Therapeutics financial statements helps investors assess Omega Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Omega Therapeutics' valuation are summarized below:
Gross Profit
-39.5 M
Market Capitalization
26.4 M
Enterprise Value Revenue
15.3358
Revenue
6.3 M
Earnings Share
(1.32)
We have found one hundred twenty available trending fundamental ratios for Omega Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Omega Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 358.4 M. The current year's Enterprise Value is expected to grow to about 301.7 M

Omega Therapeutics Total Revenue

3.74 Million

Check Omega Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Omega Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 3.1 M, Depreciation And Amortization of 8.2 M or Interest Expense of 189.8 K, as well as many indicators such as Price To Sales Ratio of 57.41, Dividend Yield of 0.0 or PTB Ratio of 2.65. Omega financial statements analysis is a perfect complement when working with Omega Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Omega Therapeutics Correlation against competitors.
For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.

Omega Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets135.9 M235 M65.2 M
Slightly volatile
Short and Long Term Debt Total155.1 M147.7 M37.8 M
Slightly volatile
Other Current Liabilities8.2 M11.4 M4.3 M
Slightly volatile
Total Current Liabilities15.5 M30.8 M8.6 M
Slightly volatile
Other Liabilities290.7 K306 K956.5 K
Slightly volatile
Property Plant And Equipment Net137.7 M131.2 M26.6 M
Slightly volatile
Accounts Payable1.9 M1.9 M1.3 M
Slightly volatile
Cash77.2 M78.7 M32.9 M
Slightly volatile
Non Current Assets Total138.2 M131.7 M28 M
Slightly volatile
Non Currrent Assets Other475.2 K500.2 K1.1 M
Pretty Stable
Other Assets443.6 K490.5 K587.1 K
Slightly volatile
Long Term Debt15.8 M17.1 M13.2 M
Slightly volatile
Cash And Short Term Investments86.8 M84.4 M36.6 M
Slightly volatile
Net Receivables8.4 MM1.6 M
Slightly volatile
Common Stock Total Equity29.1 K55.2 K17.7 K
Slightly volatile
Common Stock Shares Outstanding54 M62.1 M49.5 M
Slightly volatile
Liabilities And Stockholders Equity135.9 M235 M65.2 M
Slightly volatile
Non Current Liabilities Total144.3 M137.5 M57.7 M
Slightly volatile
Other Current Assets5.5 M10.5 M2.8 M
Slightly volatile
Other Stockholder Equity269 M451.5 M121.9 M
Slightly volatile
Total Liabilities176.7 M168.3 M67.3 M
Slightly volatile
Property Plant And Equipment Gross145 M138.1 M28.5 M
Slightly volatile
Total Current Assets103.5 M103.4 M43.8 M
Slightly volatile
Capital Stock35.4 K63.2 K19 K
Slightly volatile
Non Current Liabilities Other7.7 M7.4 M2.3 M
Slightly volatile
Net Working Capital90.8 M72.5 M36.2 M
Slightly volatile
Common Stock35.4 K63.2 K19 K
Slightly volatile
Property Plant Equipment3.9 M4.8 M3.3 M
Slightly volatile
Short and Long Term Debt3.8 M4.6 M3.3 M
Slightly volatile
Short Term DebtM17.6 M5.5 M
Slightly volatile
Long Term Debt Total14.6 M14.9 M18.8 M
Slightly volatile
Capital Surpluse373.3 M395.1 M342.3 M
Slightly volatile

Omega Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.2 M7.8 M2.4 M
Slightly volatile
Interest Expense189.8 K199.8 K529.4 K
Slightly volatile
Selling General Administrative16.5 M30.1 M10 M
Slightly volatile
Other Operating Expenses70.5 M118.9 M41.6 M
Slightly volatile
Research Development52.4 M88.7 M30.4 M
Slightly volatile
Cost Of Revenue79.5 M75.7 M14.8 M
Slightly volatile
Total Operating Expenses70.5 M118.9 M41.6 M
Slightly volatile
Reconciled Depreciation7.6 M7.3 M2.3 M
Slightly volatile
Interest Income1.7 M3.2 M662.2 K
Slightly volatile
Selling And Marketing Expenses5.4 M6.1 M6.6 M
Slightly volatile

Omega Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings7.3 M9.2 M5.5 M
Slightly volatile
Stock Based Compensation10.6 M10.1 M2.8 M
Slightly volatile
Begin Period Cash Flow64 M81.6 M31.3 M
Slightly volatile
Other Cashflows From Financing Activities171 K180 K15.7 M
Pretty Stable
Depreciation8.2 M7.8 M2.4 M
Slightly volatile
Capital Expenditures1.8 M3.3 M1.3 M
Slightly volatile
Issuance Of Capital Stock86.5 M46 M37.4 M
Slightly volatile
Total Cash From Financing Activities80.2 M48.1 M37.6 M
Slightly volatile
End Period Cash Flow77.5 M79.1 M33.3 M
Slightly volatile
Change To Netincome9.4 M8.9 M2.6 M
Slightly volatile
Change To LiabilitiesM3.3 M1.6 M
Slightly volatile
Sale Purchase Of Stock605.3 K637.2 K96.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio57.4160.432.8 K
Slightly volatile
Days Sales Outstanding9029481.2 K
Slightly volatile
Stock Based Compensation To Revenue3.13.2717.3928
Slightly volatile
Capex To Depreciation0.460.490.9638
Slightly volatile
EV To Sales78.5982.72K
Slightly volatile
Payables Turnover38.4236.597.9834
Slightly volatile
Sales General And Administrative To Revenue9.259.7388.8471
Slightly volatile
Research And Ddevelopement To Revenue27.2528.68257
Slightly volatile
Capex To Revenue1.011.077.8702
Slightly volatile
Cash Per Share1.471.220.7702
Slightly volatile
Days Payables Outstanding9.8110.32314
Slightly volatile
Income Quality0.720.850.8711
Pretty Stable
Current Ratio5.193.023.2131
Slightly volatile
Receivables Turnover0.50.40.3633
Slightly volatile
Graham Number5.695.944.3886
Slightly volatile
Capex Per Share0.0270.04780.0256
Slightly volatile
Revenue Per Share0.02760.05160.0135
Slightly volatile
Interest Debt Per Share2.252.140.6594
Slightly volatile
Debt To Assets0.720.62841.3848
Slightly volatile
Operating Cycle9029501.3 K
Very volatile
Days Of Payables Outstanding9.8110.32314
Slightly volatile
Ebt Per Ebit1.111.121.0383
Pretty Stable
Quick Ratio4.93.013.0779
Slightly volatile
Net Income Per E B T1.121.151.0395
Slightly volatile
Cash Ratio4.062.32.5552
Slightly volatile
Days Of Sales Outstanding9029481.2 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.191.0647
Slightly volatile
Fixed Asset Turnover0.02960.03120.0519
Pretty Stable
Debt Ratio0.720.62841.3848
Slightly volatile
Price Sales Ratio57.4160.432.8 K
Slightly volatile
Asset Turnover0.0080.01360.0036
Slightly volatile

Omega Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap358.4 M187 M467.5 M
Slightly volatile
Enterprise Value301.7 M255.9 M344 M
Slightly volatile

Omega Fundamental Market Drivers

Cash And Short Term Investments73.4 M

Omega Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Omega Therapeutics Financial Statements

Omega Therapeutics stakeholders use historical fundamental indicators, such as Omega Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Omega Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Omega Therapeutics' assets and liabilities are reflected in the revenues and expenses on Omega Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Omega Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.9 M-5.6 M
Total Revenue3.6 M3.7 M
Cost Of Revenue75.7 M79.5 M
Stock Based Compensation To Revenue 3.27  3.10 
Sales General And Administrative To Revenue 9.73  9.25 
Research And Ddevelopement To Revenue 28.68  27.25 
Capex To Revenue 1.07  1.01 
Revenue Per Share 0.05  0.03 
Ebit Per Revenue(29.16)(30.62)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Omega Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Omega Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Omega Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Omega Therapeutics Stock:
Check out the analysis of Omega Therapeutics Correlation against competitors.
For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.32)
Revenue Per Share
0.114
Quarterly Revenue Growth
1.812
Return On Assets
(0.25)
Return On Equity
(1.29)
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.